Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Appropriate Time for Primaquine Treatment to Reduce Plasmodium falciparum Transmission in Hypoendemic Areas

  • Wilairatana, Polrat (Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University) ;
  • Krudsood, Srivicha (Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University) ;
  • Tangpukdee, Noppadon (Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University)
  • Received : 2009.11.23
  • Accepted : 2010.03.17
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Artemesinin-combination therapies (ACT) for falciparum malaria reduce gametocyte carriage, and therefore reduce transmission. Artemisinin derivatives will act against only young gametocytes whereas primaquine acts on mature gametocytes which are present usually in the circulation at the time when the patient presents for treatment. Both artemisinin derivatives and primaquine have short half-lives, less than 1 hr and 7 hr, respectively. Therefore, asexual parasites or young gametocytes remain after completed ACT. A single dose of primaquine (0.50-0.75 mg base/kg) at the end of ACT can kill only mature gametocytes but cannot kill young gametocytes (if present). Remaining asexual forms after completion of ACT course, e.g., artesunate-mefloquine for 3 days, may develop to mature gametocytes 7-15 days later. Thus, an additional dose of primaquine (0.50-0.75 mg base/kg) given 2 weeks after ACT completion may be beneficial for killing remaining mature gametocytes and contribute to more interruption of Plasmodium falciparum transmission than giving only 1 single dose of primaquine just after completing ACT.

Keywords

References

  1. Rieckmann KH, McNamara JV, Frischer H, Stockert TA, Carson PE, Powell RD. Gametocidal and sporontocidal effects of primaquine and of sulfadoxine with pyrimethamine in a chloroquineresistant strain of Plasmodium falciparum. Bull WHO 1968; 38: 625-632.
  2. Lawpoolsri S, Klein EY, Singhasivanon P, Yimsamran S, Thanyavanich N, Maneeboonyang W, Hungerford LL, Maguire JH, Smith DL. Optimal timing of primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations. Malaria J 2009; 8: 159. https://doi.org/10.1186/1475-2875-8-159
  3. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39: 1336-1345. https://doi.org/10.1086/424663
  4. World Health Organization. Guidelines for the treatment of malaria. 1st ed. Geneva, Switzerland. WHO. 2006. p 71, 133-143.
  5. Tangpukdee N, Krudsood S, Srivilairit S, Phophak N, Chonsawat P, Yanpanich W, Kano S, Wilairatana P. Gametocyte clearance in uncomplicated and severe Plasmodium falciparum malaria after astesunate-mefloquine treatment in Thailand. Korean J Parasitol 2008; 46: 65-70. https://doi.org/10.3347/kjp.2008.46.2.65
  6. Piyaphanee W, Krudsood S, Tangpukdee N, Thanachartwet W, Silachamroon U, Phophak N, Duangdee C, Haoharn O, Faithong S, Wilairatana P, Leowattana W, Looareesuwan S. Emergence and clearance of gametocytes in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2006; 74: 432-435.
  7. Na-Bangchang K, Karbwang J. Clinical pharmacology of primaquine. In: Karbwang J, Wernsdorfer W eds, Clinical Pharmacology of Antimalarials (1st ed.). Bangkok, Thailand. Clinical Pharmacology Unit, Faculty of Tropical Medicine, Mahidol University. 1993, p 316.
  8. Githeko AK, Brandling-Bennett AD, Beier M, Atieli F, Owaga M, Collins FH. The reservoir of Plasmodium falciparum malaria in a holoendmic area of western Kenya. Trans R Soc Trop Med Hyg 1992; 86: 355-358. https://doi.org/10.1016/0035-9203(92)90216-Y
  9. Nassir E, Abdel-Muhsin AM, Suliaman S, Kenyon F, Kheir A, Geha H, Ferguson HM, Walliker D, Babiker HA. Impact of genetic complexity on longevity and gametocytogenesis of Plasmodium falciparum during the dry and transmission-free season of eastern Sudan. Int J Parasitol 2005; 35: 49-55. https://doi.org/10.1016/j.ijpara.2004.10.014
  10. Schneider P, Schoone G, Schallig H, Verhage D, Telgt D, Eling W, Sauerwein R. Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. Mol Biochem Parasitol 2004; 137: 35-41. https://doi.org/10.1016/j.molbiopara.2004.03.018
  11. Schneider P, Bousema T, Omar S, Gouagna L, Sawa P, Schallig H, Sauerwein R. (Sub)microscopic Plasmodium falciparum gametocytemia in Kenyan children after treatment with sulfadoxinepyrimethamine monotherapy or in combination with artesunate. Int J Parasitol 2006; 36: 403-408. https://doi.org/10.1016/j.ijpara.2006.01.002
  12. White NJ. The role of anti-malarial drugs in eliminating malaria. Malaria J 2008; 7(suppl 1): S8. https://doi.org/10.1186/1475-2875-7-S1-S8
  13. Talman AM, Paul RE, Sokhna CS, Domarle O, Ariey F, Trape JF, Robert V. Influence of chemotherapy on the Plasmodium gametocyte sex ratio of mice and humans. Am J Trop Med Hyg 2004; 71: 739-744.
  14. Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V. Gametocytogenesis: the puberty of Plasmodium falciparum. Malar J 2004; 3: 24. https://doi.org/10.1186/1475-2875-3-24
  15. Eichner M, Diebner HH, Molineaux L, Collins WE, Jeffery GM, Dietz K. Genetics, sequestration and survival of Plasmodium falciparum gametocytes: parameter estimates from fitting a model tomalaria therapy data. Trans R Soc Trop Med Hyg 2001; 95: 497- 501. https://doi.org/10.1016/S0035-9203(01)90016-1
  16. Robert V, Boudin C. Biologie de la transmission homme-moustique du Plasmodium. Bull Soc Pathol Exot 2003; 96: 6-20.
  17. Sinden RE. Sexual development of malaria parasite. Adv Parasitol 1983; 22: 153-216. https://doi.org/10.1016/S0065-308X(08)60462-5
  18. Smalley ME, Sinden RE. Plasmodium falciparum gametocytes: their longevity and infectivity. Parasitology 1977; 74: 1-8. https://doi.org/10.1017/S0031182000047478
  19. Field JW, Shute PG. The microscopic diagnostic of human malaria. In A Morphological Study of the Erythrocytic Parasites. Kuala Lumpur, Malaysia. Government Press. 1956, p 142.
  20. Pukrittayakamee S, Imwong M, Stepniewska K, Day NPJ, White NJ. The effects of different antimalarial drugs on gametocyte carriage in Plasmodium vivax malaria. Am J Trop Med Hyg 2008; 79: 378-384.

Cited by

  1. Methodology and application of flow cytometry for investigation of human malaria parasites vol.367, pp.1, 2010, https://doi.org/10.1016/j.jim.2011.01.015
  2. Plasmodium cell biology should inform strategies used in the development of antimalarial transmission-blocking drugs vol.4, pp.18, 2010, https://doi.org/10.4155/fmc.12.182
  3. Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis vol.6, pp.1, 2013, https://doi.org/10.1186/1756-3305-6-278
  4. Strategic use of antimalarial drugs that block falciparum malaria parasite transmission to mosquitoes to achieve local malaria elimination vol.113, pp.10, 2014, https://doi.org/10.1007/s00436-014-4091-6
  5. Plasmodium transmission blocking activities of Vernonia amygdalina extracts and isolated compounds vol.14, pp.None, 2010, https://doi.org/10.1186/s12936-015-0812-2
  6. Transmission-blocking strategies: the roadmap from laboratory bench to the community vol.15, pp.None, 2010, https://doi.org/10.1186/s12936-016-1163-3
  7. Extended-spectrum antiprotozoal bumped kinase inhibitors: A review vol.180, pp.None, 2010, https://doi.org/10.1016/j.exppara.2017.01.001